And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans. Our agenda is rather modest. We plan to hang with our short people, catch up on our reading and napping, and promenade with the official mascots. And what about you? Winter is clearly on its way, so perhaps you want to give the economy another boost by purchasing a sweater or something else that is warm and fuzzy. You could make time to reach out to someone special. Or given recent events, this may be a good time to take stock and count your blessings, not your faults. Well, whatever you do, have a grand time. But be safe. Enjoy, and see you soon …

AstraZeneca (AZN) disclosed that its Imfinzi immunotherapy did not meet the main goal of improving survival rates for patients with the most advanced form of lung cancer, putting pressure on its shares, Reuters writes. The study, known as MYSTIC, was among the industry’s most anticipated clinical experiments and was viewed as central to proving the value of its new drug pipeline and future as an independent company, after spurning a $118 billion takeover attempt by Pfizer. The trial looked at stage IV patients — those with the most advanced form of cancer.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy